搜索结果

Search Results for " b-cll cells "

Targets Recommended: Topoisomerase PKC

抑制剂 & 化合物

重组蛋白

同位素标记化合物

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T6588	Mitoxantrone 米托蒽醌,mitozantrone	Topoisomerase; PKC	Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair
	Mitoxantrone (mitozantrone) 是一种拓扑异构酶 II (Topo II) 的抑制剂，一种蛋白激酶 C (PKC) 的抑制剂 (IC50=8.5 μM)。Mitoxantrone 具有抗肿瘤活性，可以治疗急性髓系白血病、肝细胞癌、乳腺癌等。
T0158	Mitoxantrone dihydrochloride 米托蒽醌二盐酸盐,盐酸米托蒽醌,Mitoxantrone 2HCl,Mitoxantrone hydrochloride,NSC-301739,mitozantrone dihydrochloride	Topoisomerase; PKC	Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair
	Mitoxantrone dihydrochloride (NSC-301739) 是一种拓扑异构酶 II 的抑制剂；也可抑制蛋白激酶C (PKC)，IC50值为8.5 μM。
T14847	B I09	Others; IRE1	Cell Cycle/Checkpoint; Others
	B I09是一种 IRE-1 RNase 抑制剂，IC50为1230 nM，对人 WaC3细胞中 XBP1 mRNA 的剪接和 LPS 刺激的 B 细胞中 xbp -1的表达有抑制作用。B I09可用于 CLL 细胞模拟XBP-1缺陷的研究。
T14919	CDKI-73	Apoptosis; CDK	Apoptosis; Cell Cycle/Checkpoint
	CDKI-73 是一种具有口服活性的 CDK9抑制剂，其对 CDK9、CDK1 和 CDK2 的Ki 值分别为 4 nM、4 nM 和 3 nM。CDKI-73 可下调 RNA 聚合酶 II 的磷酸化。CDKI-73 也是一种 Rab11 的抑制剂。
T3626	Acalabrutinib ACP-196,阿可替尼	BTK	Angiogenesis; Tyrosine Kinase/Adaptors
	Acalabrutinib (ACP-196) 是一种不可逆的、高效的、具有口服活性、选择性的第二代BTK 抑制剂。它与 BTK 的 ATP 结合口袋中的 Cys481 共价结合。它在慢性淋巴细胞性白血病 (CLL) 小鼠模型中显示出强大的靶向作用和功效。

化合物

Mitoxantrone

Cat.No: T6588

Synonym: 米托蒽醌,mitozantrone

Target: Topoisomerase, PKC

Mitoxantrone dihydrochloride

Cat.No: T0158

Synonym: 米托蒽醌二盐酸盐,盐酸米托蒽醌,Mitoxantrone 2HCl,Mitoxantrone hydrochloride,NSC-301739,mitozantrone dihydrochloride

Target: Topoisomerase, PKC

B I09

Cat.No: T14847

Synonym:

Target: Others, IRE1

CDKI-73

Cat.No: T14919

Synonym:

Target: Apoptosis, CDK

Acalabrutinib

Cat.No: T3626

Synonym: ACP-196,阿可替尼

Target: BTK

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPY-04272	FcRH2/FCRL2 Protein, Human, Recombinant (His) IFGP4,FCRH2,CD307b,SPAP1,SPAP1B,Fc recepto...	Human	HEK293 Cells
	Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. FCRL2 has robust predictive value for determining IGHV gene mutation status and clinical progression and thus may further improve prognostic definition in CLL (B-cell chronic lymphocytic leukemia).
TMPK-00234	CD84 Protein, Human, Recombinant (His & Avi) CD84,DKFZp781E2378,Hly9-beta,Hly9-β,CD84 molecule,S...	Human	HEK293 Cells
	Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5 B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells.
TMPK-01413	H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) H-2K,OVA,MHC,H2-K1	Mouse	HEK293 Cells
	Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se...
TMPK-01412	HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) SARS-CoV-2 epitope,MHC	Human	HEK293 Cells
	HLA-B15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells* from pre-pandemic individuals carrying HLA-B15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells* displayed memory phenotype.
TMPK-01416	HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated MHC,SARS-CoV-2 epitope	Human	HEK293 Cells
	HLA-B15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells* from pre-pandemic individuals carrying HLA-B15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells* displayed memory phenotype.

重组蛋白

FcRH2/FCRL2 Protein, Human, Recombinant (His)

Cat.No: TMPY-04272

Species: Human

Expression System: HEK293 Cells

CD84 Protein, Human, Recombinant (His & Avi)

Cat.No: TMPK-00234

Species: Human

Expression System: HEK293 Cells

H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi)

Cat.No: TMPK-01413

Species: Mouse

Expression System: HEK293 Cells

HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01412

Species: Human

Expression System: HEK293 Cells

HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01416

Species: Human

Expression System: HEK293 Cells

Cat. No.	Product Name	Target	Signaling Pathways
TMIH-0065	Acalabrutinib-d4
	Acalabrutinib-d4 是 Acalabrutinib 的氘代化合物。Acalabrutinib 的 CAS 号为 1420477-60-6。Acalabrutinib 是一种不可逆的、高效的、具有口服活性、选择性的第二代BTK抑制剂。它与 BTK 的 ATP 结合口袋中的 Cys481 共价结合。它在慢性淋巴细胞性白血病 (CLL) 小鼠模型中显示出强大的靶向作用和功效。

同位素标记化合物

Acalabrutinib-d4

Cat.No: TMIH-0065

Synonym:

Target:

* 搜索：		* 机关/企业：
* 邮箱：		* 电话：
备注：
验证码：

搜索结果

抑制剂 & 化合物

重组蛋白

同位素标记化合物

提交您的定制咨询

化合物

重组蛋白

同位素标记化合物